Browse treatments

…ing the tumor endothelial barrier, potentially synergizing with PD-L1 blockade. The EORTC-1508GCG phase II trial evaluated atezolizumab (anti-…

…b with platinum (cisplatin/carboplatin) and pemetrexed prior to P/D (2 cycles) for patients with resectable DPM ( NCT04162015).Meth…

…ation remains limited by significant toxicities associated with lymphodepleting chemotherapy and high-dose IL-2 regimens. Phase 1 trial TUNINTIL ( NCT042174…

…composition of T cells subpopulations.Results Upon treatment of triplet therapy, tumors of responders exhibited upregulation of inflammatory ge…

…pediatric solid tumors continue to have poor clinical outcomes. NK cell immunotherapies, though promising, face challenges with NK cell expansion, pers…

… treatment outcomes in stage III cutaneous melanoma compared to adjuvant therapy. However, real-world data (RWD) on neoadjuvant immunotherapy re…

…ceived a more effective (and less expensive) treatment, such as chemotherapy, if their ‘non-response’ status could have been predicted at ba…

…r cells in the TME can support elucidation of complex MOAs with antibody-drug conjugate (ADC) therapies. TV is a tissue factor-directed ADC hypothesized to drive apopt…

…also emerging as clinical biomarkers and a mechanism to deliver treatments. However, the variability in EV characterization and analysis a…

… of systemic treatment, including at least one line of ICIs and platinum-based chemotherapy. Participants will be randomized 1:1 to receive either THIO 180…

… who had relapsed after 2 prior treatments which had prior ICI, Chemotherapy and Docetaxel. Eligible patients must have histologically confi…

…clinical efficacy in SCLC patients with previously treated with chemoimmunotherapy. However, the duration of treatment response is short, and the …